Publications

Nature

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

18-06-2015

Nature

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

28-05-2015

International journal of cancer

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

15-03-2015

Genome biology

CopywriteR: DNA copy number detection from off-target sequence data.

27-02-2015

Cancer research

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

15-02-2015

The EMBO journal

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.

03-02-2015

J Pathol.: The journal of pathology

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase

23-01-2015

J Proteome Res.: Journal of proteome research

The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer

20-01-2015

Cell reports

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

20-01-2015

Cell death & disease

Suppression of BRCA1 sensitizes cells to proteasome inhibitors.

18-12-2014

Nucleic Acids Res.: Nucleic Acids research

INFRAFRONTIER--providing mutant mouse resources as research tools for the international scientific community

20-11-2014

Cell

Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.

23-10-2014

Nature biotechnology

Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping.

01-10-2014

Proceedings of the National Academy of Sciences of the United States of America

Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress.

16-09-2014

Clinical cancer research : an official journal of the American Association for Cancer Research

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.

15-09-2014

Cancer discovery

Patient-derived xenograft models: an emerging platform for translational cancer research.

01-09-2014

PloS one

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

02-08-2014

Oncogene

Opportunities and hurdles in the treatment of BRCA1-related breast cancer.

17-07-2014

British journal of cancer

Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.

27-05-2014

Breast Cancer Research: BRC

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

15-05-2014

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

01-02-2014

EMBO molecular medicine

Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells.

01-02-2014

Cell death and differentiation

Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential.

01-02-2014

Cancer discovery

A high-throughput functional complementation assay for classification of BRCA1 missense variants.

01-10-2013

Stem Cells (Dayton, Ohio)

Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal

01-09-2013

Stem cells (Dayton, Ohio)

Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool.

01-09-2013

J Exp Med.: The journal of experimental medicine

BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival

15-07-2013

Scientific reports

Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance.

07-06-2013

Cancer Research

Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling

03-06-2013

Nat Commun.: Nature communications

ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets

01-06-2013

PloS one

Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors.

22-05-2013

Proc Natl Acad Sci U S A: Proceedings of the National Academy of Siences of the United States of America

Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer

08-05-2013

Molecular oncology

Genetically engineered mouse models of PI3K signaling in breast cancer.

01-04-2013

The Journal of pathology

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

01-03-2013

Mol Cell Proteomics: Molecular & cellular proteomics: MCP

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance

08-02-2013

PLoS One

Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS

11-01-2013

Cancer discovery

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

01-01-2013

Cancer research

A preclinical mouse model of invasive lobular breast cancer metastasis.

01-01-2013

Genes Dev.: Genes & development

BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny

27-12-2012

The Journal of pathology

Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland.

01-11-2012

PloS one

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

03-10-2012

Nature reviews. Cancer

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

01-09-2012

Cancer prevention research (Philadelphia, Pa.)

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

01-08-2012

Cancer discovery

Tracking evolution of BRCA1-associated breast cancer.

01-06-2012

Cancer research

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

01-05-2012

Nat Med: Nature medicine

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

06-03-2012

Drug Resist Updates: reviews and commentaries in antimicrobial and anticancer chemotherapy

A rapidly growing number of therapeutics targeting tumor cell-intrinsic and -extrinsic processes is under development for individualized treatment of cancer patients

01-03-2012

Mol Cell Proteomics: Molecular & cellular proteomics: MCP

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer

24-02-2012

Nature

Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.

22-02-2012

Current opinion in genetics & development

Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.

01-02-2012

IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.

CopywriteR: DNA copy number detection from off-target sequence data.

BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistance.

BRCA1 and CtIP promote alternative non-homologous end-joining at uncapped telomeres.

Spontaneous bone metastases in a preclinical orthotopic model of invasive lobular carcinoma; the effect of pharmacological targeting TGFβ receptor I kinase

The use of mass spectrometry imaging to predict treatment response of patient-derived xenograft models of triple-negative breast cancer

Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression.

Suppression of BRCA1 sensitizes cells to proteasome inhibitors.

INFRAFRONTIER--providing mutant mouse resources as research tools for the international scientific community

Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways.

Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping.

Chromosome instability induced by Mps1 and p53 mutation generates aggressive lymphomas exhibiting aneuploidy-induced stress.

Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment.

Patient-derived xenograft models: an emerging platform for translational cancer research.

Lack of genomic heterogeneity at high-resolution aCGH between primary breast cancers and their paired lymph node metastases.

Opportunities and hurdles in the treatment of BRCA1-related breast cancer.

Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.

Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells.

Epidermal Snail expression drives skin cancer initiation and progression through enhanced cytoprotection, epidermal stem/progenitor cell expansion and enhanced metastatic potential.

A high-throughput functional complementation assay for classification of BRCA1 missense variants.

Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal

Polycomb group gene Ezh2 regulates mammary gland morphogenesis and maintains the luminal progenitor pool.

BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival

Defined lipid analogues induce transient channels to facilitate drug-membrane traversal and circumvent cancer therapy resistance.

Loss of p120-catenin induces metastatic progression of breast cancer by inducing anoikis resistance and augmenting growth factor receptor signaling

ARF triggers senescence in Brca2-deficient cells by altering the spectrum of p53 transcriptional targets

Analysis of tumor heterogeneity and cancer gene networks using deep sequencing of MMTV-induced mouse mammary tumors.

Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer

Genetically engineered mouse models of PI3K signaling in breast cancer.

An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.

Proteomics of genetically engineered mouse mammary tumors identifies fatty acid metabolism members as potential predictive markers for cisplatin resistance

Use of a single hybrid imaging agent for integration of target validation with in vivo and ex vivo imaging of mouse tumor lesions resembling human DCIS

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.

A preclinical mouse model of invasive lobular breast cancer metastasis.

BRCA1 deficiency in skin epidermis leads to selective loss of hair follicle stem cells and their progeny

Developmental stage-specific contribution of LGR5(+) cells to basal and luminal epithelial lineages in the postnatal mammary gland.

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.

The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol.

Tracking evolution of BRCA1-associated breast cancer.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system

A rapidly growing number of therapeutics targeting tumor cell-intrinsic and -extrinsic processes is under development for individualized treatment of cancer patients

Proteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancer

Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours.

Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.

This site uses cookies